CAS: 146987-10-2; (S)-2-((((9H-Fluoren-9-yl)Methoxy)Carbonyl)Amino)-6-(5-((3As,4S,6Ar)-2-Oxohexahydro-1H-Thieno[3,4-D]Imidazol-4-yl)Pentanamido)Hexanoic Acid

相似化合物

62062-43-5 1159531-18-6 201485-17-8

上下游产品

CAS号105047-45-8 n-芴甲氧羰基-l-赖氨酸 | CAS号58-85-5 D-生物素 | CAS号35013-72-0 (+)生物素-N-琥珀酰亚胺基酯 | CAS号71989-26-9 Nα-芴甲氧羰基-Nε-叔丁氧...

D-生物素置于盐酸-N-乙基-N'-(3-二甲氨基丙基)碳二亚胺,Sodium Hydroxide体系中,用 1,4-二氧六环,水,N,N-二甲基甲酰胺 用作溶剂,化学反应生成N-Fmoc-N'-生物素-L-赖氨酸
参考文献:Identification Of Annexin A2 As A Target Protein For Plant Alkaloid Matrine
标题:Identification Of Annexin A2 As A Target Protein For Plant Alkaloid Matrine
摘要:甲硷的细胞靶标已经确定.
Doi:10.1039/c7Cc02227A

专利信息

专利号:US-2004265949-A1
优先权日:2003-06-26
标题:Method and building blocks for preparing C-terminally labelled peptides
发明人：WHITE PETER DAVID; BEYTHIEN JORG KARL WILHEIM
摘要:A method for preparing C-terminally labelled peptides and building blocks to be used in this synthesis includes a trivalent nitrogen atom having at least one device for attachment to a solid support, one device for the attachment of amino acids and one device for attachment of a label, whereby the device for the attachment of amino acids and/or the device for the attachment of a label is a linker, e.g. an alkyl- or polyethyleneglycol- linker.

专利号:US-2012129764-A1
优先权日:2009-05-08
标题 :Influenza a and b virus replication-inhibiting peptides
发明人：KESSLER ULRICH; MAYER DANIEL; WUNDERLICH KERSTIN; RNADHEERA CHARLENE; SCHWEMMLE MARTIN
权利人:KESSLER ULRICH; MAYER DANIEL; WUNDERLICH KERSTIN; RNADHEERA CHARLENE; SCHWEMMLE MARTIN; PIKE PHARMA GMBH
摘要:A synthesized or isolated influenza virus replication-inhibiting peptide that competitively inhibits protein-protein interaction of the PA and PB1 of both influenza Virus Types A and B and novel in vitro binding screen to identify peptides with antiviral activity against influenza viruses of both type A and B is disclosed. In addition to the well-known pandemic influenza A viruses (such as the 1918 “Spanishâ€? flu or H5N1), both type A and B viruses contribute greatly to the annual recurring epidemics that cause the vast majority of human cases and medical cost. Surprisingly, it was found that the novel virus replication-inhibiting, are able to inhibit protein-protein interaction of the PA and PB1 subunits of the heterotrimeric viral RNA polymerase complex of both influenza virus types A and B. The viral polymerase sub-unit interaction domain turned out as an effective target for the new antivirals, as correct assembly of the three viral polymerase subunits PB1, PB2 and PA is required for viral RNA synthesis and infectivity.